Core Viewpoint - The company, Jianyou Co., Ltd. (stock code: 603707), announced a share buyback program, having repurchased a total of 1.379995 million shares, which represents 0.09% of its total share capital as of October 31, 2025 [1] Summary by Category - **Share Buyback Details** - The company has conducted a share buyback through the Shanghai Stock Exchange trading system via centralized bidding [1] - The total number of shares repurchased is 1.379995 million [1] - This repurchase accounts for 0.09% of the company's total share capital [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has announced a share buyback program, indicating a commitment to returning value to shareholders through capital management strategies [1] Summary by Categories Share Buyback Details - As of October 31, 2025, the company has repurchased a total of 1.379995 million shares, which represents 0.09% of the company's total share capital [1] - The lowest transaction price during the buyback was 9.56 yuan per share, while the highest was 11.66 yuan per share [1] - The total amount spent on the buyback reached approximately 15.0085 million yuan, excluding transaction fees and stamp duty [1]

| | | 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）于 2025 年 4 月 28 日召开了第五届董事会第十二次会议，审议通过了《关于拟通过集中竞 价方式回购股票的议案》，并经 2025 年 5 月 20 日召开的公司 2024 年年度股东 大会审议通过。 本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万 元（含），本次回购股份的价格不超过 18.75 元/股（含），本次回购的股份用于 员工持股计划或股权激励，回购股份实施期限为自公司股东大会审议通过本次回 购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 29 日披露的《健 友股份关于以集中竞价交易方式回购股份的预案》（公告编号：2025-028）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引 ...

南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议资料 公司代码：603707 公司简称：健友股份 南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议资料 2025 年 11 月 12 日 | 2025 | 年第一次临时股东大会会议须知 3 | | --- | --- | | 2025 | 年第一次临时股东大会会议议程 5 | | | 关于变更注册资本、取消监事会并修订公司章程的议案 7 | | | 关于修订公司相关制度及工作细则的议案 45 | 南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议资料 南京健友生化制药股份有限公司 2025 年第一次临时股东大会会议须知 为维护全体股东的合法权益，确保南京健友生化制药股份有限公 司（以下简称"公司"）股东大会的正常秩序和议事效率，保证股东 大会的顺利进行，根据公司《股东大会议事规则》的规定，特制定本 次股东大会须知如下： 一、公司根据《中华人民共和国公司法》、《中华人民共和国证 券法》、《南京健友生化制药股份有限公司章程》及《股东大会议事 规则》的规定，认真做好股东大会的各项工作。 二、出席本次股东大会现场会议的股东及 ...

Summary of Key Points Core Viewpoint - The company, Jianyou Co., has announced a share buyback program, indicating a strategic move to enhance shareholder value amidst market conditions [1]. Group 1: Share Buyback Details - As of October 31, 2025, Jianyou Co. has repurchased approximately 1.38 million shares through the Shanghai Stock Exchange, representing 0.09% of the company's total share capital [1]. - The shares were bought at a minimum price of 9.56 CNY per share and a maximum price of 11.66 CNY per share [1]. - The total amount spent on the share buyback is approximately 15.01 million CNY [1].

Core Viewpoint - Jianyou Co., Ltd. is a leading domestic heparin raw material enterprise with a complete heparin industry chain, showcasing strong technical capabilities and market competitiveness in both raw materials and formulations [1] Group 1: Business Performance - In Q3 2025, Jianyou's revenue reached 2.926 billion yuan, ranking 25th out of 110 in the industry, with the industry leader, Huadong Medicine, generating 32.664 billion yuan [2] - The net profit for the same period was 429 million yuan, placing the company 19th in the industry, while the top performer, Heng Rui Medicine, reported a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Jianyou's debt-to-asset ratio was 34.50%, slightly up from 33.52% year-on-year, which is below the industry average of 35.26%, indicating relatively good debt repayment capability [3] - The gross profit margin for Q3 2025 was 39.48%, down from 41.41% year-on-year, and below the industry average of 57.17%, suggesting a need for improvement in profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 22.47% to 29,200, while the average number of circulating A-shares held per shareholder decreased by 18.35% to 55,300 [5] - The top ten circulating shareholders included E Fund Quality Momentum Three-Year Holding Mixed Fund, holding 12.4865 million shares, unchanged from the previous period [5] Group 4: Management Compensation - The chairman and general manager, Tang Yongqun, received a salary of 1.5 million yuan in 2024, which remained unchanged from 2023 [4] Group 5: Analyst Insights - Huatai Securities maintains a "buy" rating, predicting net profits for 2025-2027 to be 671 million, 846 million, and 1.199 billion yuan, respectively, with a target price of 10.24 yuan based on a 2026 PE of 19.55x [5] - Ping An Securities has adjusted its net profit forecasts for 2025-2026 to 753 million and 866 million yuan, respectively, while expecting a rebound in performance due to the upcoming volume release of biosimilars [6]

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.28% on October 30, with Hanyu Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Notable gainers included: - C Bietete (688759) with a closing price of 34.82, up 9.29% and a trading volume of 219,800 shares, totaling 732 million yuan [1] - Changshan Pharmaceutical (300255) closed at 63.50, up 8.51% with a trading volume of 493,200 shares, totaling 3.073 billion yuan [1] - Significant losers included: - Hanyu Pharmaceutical (300199) closed at 20.01, down 10.23% with a trading volume of 1,135,400 shares, totaling 232.7 million yuan [2] - Kangyi Pharmaceutical (300086) closed at 7.44, down 7.81% with a trading volume of 947,500 shares, totaling 713 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.268 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.508 billion yuan [2] - The capital flow for specific stocks showed: - Changshan Pharmaceutical had a net inflow of 74.5152 million yuan from institutional investors [3] - Hanyu Pharmaceutical experienced a net outflow of 60.3884 million yuan from retail investors [3]

Summary of the Conference Call for Jianyou Co., Ltd. Company Overview - **Company**: Jianyou Co., Ltd. - **Date**: October 24, 2025 Key Points Financial Performance - Revenue for the first three quarters of 2025 decreased by 5.25% year-on-year to 3.09 billion RMB, while net profit fell by 29% to 430 million RMB, primarily due to increased sales and management expenses, especially in the U.S. market [2][3] - The total assets reached 10.3 billion RMB, with net assets attributable to shareholders at 6.75 billion RMB [3] Sales and Management Expenses - Sales expenses increased by approximately 90 million RMB, and management expenses rose by about 50 million RMB, largely due to investments in the U.S. market for large molecules and innovative drugs [4] - The company expects total revenue for the year to be between 4.2 billion and 4.4 billion RMB, with profits around 600 million to 700 million RMB [4] Raw Material and CDMO Business - The raw material segment saw a revenue decline of 37% year-on-year, with net gross profit down 40%. However, a 15% price increase is anticipated due to rising demand for high-quality raw materials [10] - CDMO business revenue decreased by 60%, but excluding certain sales impacts, it remained stable year-on-year, with future order growth expected at 25%-30% [11] Domestic and International Formulations - Domestic formulation shipments fell by 13% year-on-year, with gross profit declining over 20% due to price reductions following contract renewals [12] - International formulations performed well, with sales volume increasing by 21% and revenue up 32%, significantly driven by the U.S. market [14] Major Products and Market Competition - Three main large molecule products (White Purple, Adalimumab) maintained stable market shares, although White Purple faced pricing competition [8] - The company expects total revenue from these products to be adjusted to 65 million USD, with a net gross profit of 30 million USD for the year [9][16] Innovative Drug Development - The M22 Phase II clinical trial was completed, showing that 50% of patients could discontinue hormone treatment within six months. Discussions with the FDA for Phase III are ongoing [7] - The company plans to launch three insulin products in collaboration with Dongbao, targeting a 15%-20% market share within 4-6 quarters [17] R&D and Future Strategy - R&D expenses increased by 45 million RMB year-on-year, with five new projects initiated in the peptide large molecule field [6] - The company aims for large molecule drugs to account for over 60% of revenue by 2030, with a focus on expanding in the U.S. and European markets [4][22] Market Environment and Regulatory Changes - The FDA's easing of clinical requirements for biosimilars is expected to intensify competition but also provide opportunities for efficient companies [21] - The company is adapting its strategy to increase the proportion of self-completed projects in the large molecule field, aiming for 40%-50% by the end of 2025 [23] Challenges and Opportunities - The company faces challenges from pricing pressures and competition but is optimistic about future growth driven by innovative drug development and market expansion [31][33] - The strategic focus includes enhancing R&D capabilities and leveraging regulatory changes to improve market positioning [32] Conclusion - Jianyou Co., Ltd. is navigating a challenging market environment with a strategic focus on innovation and expansion in large molecule drugs, while addressing cost pressures and competition effectively. The company is well-positioned for future growth, with a clear roadmap for product development and market penetration.

Core Insights - The company reported a revenue of 2.926 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 5.25% [1] - The net profit attributable to the parent company was 429 million yuan, down 29.11% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 384 million yuan, a decrease of 29.95% year-on-year [1] - The basic earnings per share stood at 0.27 yuan [1]

Group 1 - The core point of the article is that Jianyou Co., Ltd. (SH 603707) held its 15th meeting of the 5th board of directors on October 24, 2025, to review the proposal for the company's Q3 2025 report [1] - For the year 2024, Jianyou Co., Ltd.'s revenue composition is 99.85% from the pharmaceutical manufacturing industry and 0.15% from other businesses [1] - As of the report date, Jianyou Co., Ltd. has a market capitalization of 15.6 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]